Literature DB >> 2350510

Responses of killer cells in head and neck cancer patients.

S Fujieda1, H Saito, T Hoshino.   

Abstract

The immunological functions of 60 patients with head and neck cancers were evaluated using in vitro natural killer cell (NK) activity, lymphokine activated killer cells (LAK) and OK-432 activated killer cells, as well as by in vivo purified protein derivative (PPD) and Su-PS skin tests. There were significant differences of the above three activities between stage I cancer patients and stage III and/or IV. The PPD skin test corresponded significantly to LAK activity, while Su-PS corresponded significantly to OK-432 activated killer cell activity. Responses to interleukin-2 and OK-432 of stage IV patients with head and neck cancers were different from those of stage IV with gastrointestinal cancer. These in vitro assays were very useful for the evaluation of immunological function in head and neck cancer patients, especially before any biological response modifying treatment.

Entities:  

Mesh:

Year:  1990        PMID: 2350510     DOI: 10.1007/bf00175973

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  33 in total

1.  Modulation of natural killer cell activity by serum from cancer patients: preliminary results of a study of patients with colorectal adenocarcinoma or other types of cancer.

Authors:  M Pislarasu; A Oproiu; D Taranu; R B Herberman; A Sulica
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

2.  Natural killer cell activity and head and neck cancer: a clinical assessment.

Authors:  S P Schantz; E J Shillitoe; B Brown; B Campbell
Journal:  J Natl Cancer Inst       Date:  1986-10       Impact factor: 13.506

3.  Abnormalities of quantitative dinitrochlorobenzene sensitization in cancer patients: correlation with tumor stage and histology.

Authors:  W J Catalona; P B Chretien
Journal:  Cancer       Date:  1973-02       Impact factor: 6.860

4.  Comparison of immune derangements in patients with different malignancies.

Authors:  A Lichtenstein; J Zighelboim; F Dorey; S Brossman; J L Fahey
Journal:  Cancer       Date:  1980-04-15       Impact factor: 6.860

5.  Potential uses of interleukin 2 in cancer therapy.

Authors:  M A Cheever; J A Thompson; D J Peace; P D Greenberg
Journal:  Immunobiology       Date:  1986-09       Impact factor: 3.144

6.  Eradication of disseminated murine leukemia by treatment with high-dose interleukin 2.

Authors:  J A Thompson; D J Peace; J P Klarnet; D E Kern; P D Greenberg; M A Cheever
Journal:  J Immunol       Date:  1986-12-01       Impact factor: 5.422

7.  Evidence for the role of natural immunity in the control of metastatic spread of head and neck cancer.

Authors:  S P Schantz; B W Brown; E Lira; D L Taylor; N Beddingfield
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

8.  Modulation of NK activity in regional lymph nodes by preoperative immunotherapy with OK-432 in patients with cancer of the oral cavity.

Authors:  K Vinzenz; M Matejka; G Watzek; H Porteder; N Neuhold; M Micksche
Journal:  Cancer Detect Prev Suppl       Date:  1987

9.  Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.

Authors:  P M Sondel; P C Kohler; J A Hank; K H Moore; N S Rosenthal; J A Sosman; R Bechhofer; B Storer
Journal:  Cancer Res       Date:  1988-05-01       Impact factor: 12.701

10.  In vivo induction of the lymphokine-activated killer phenomenon: interleukin 2-dependent human non-major histocompatibility complex-restricted cytotoxicity generated in vivo during administration of human recombinant interleukin 2.

Authors:  J A Hank; P C Kohler; G Weil-Hillman; N Rosenthal; K H Moore; B Storer; D Minkoff; J Bradshaw; R Bechhofer; P M Sondel
Journal:  Cancer Res       Date:  1988-04-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.